PL377740A1 - Kompozycje farmaceutyczne ze zmodyfikowaną zaróbką - Google Patents

Kompozycje farmaceutyczne ze zmodyfikowaną zaróbką

Info

Publication number
PL377740A1
PL377740A1 PL377740A PL37774003A PL377740A1 PL 377740 A1 PL377740 A1 PL 377740A1 PL 377740 A PL377740 A PL 377740A PL 37774003 A PL37774003 A PL 37774003A PL 377740 A1 PL377740 A1 PL 377740A1
Authority
PL
Poland
Prior art keywords
pharmaceutical compositions
modified vehicle
modified
vehicle
pharmaceutical
Prior art date
Application number
PL377740A
Other languages
English (en)
Inventor
Ondrej Hendl
Susan Marie Machkovech
Niki Ann Waldron
Nancy Jean Britten
Dannette Marie Shaw
Alanta Lea Lary
Thomas Joseph Yellig
Original Assignee
Pharmacia & Upjohn Company Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32326579&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL377740(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pharmacia & Upjohn Company Llc filed Critical Pharmacia & Upjohn Company Llc
Publication of PL377740A1 publication Critical patent/PL377740A1/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cephalosporin Compounds (AREA)
PL377740A 2002-11-19 2003-11-17 Kompozycje farmaceutyczne ze zmodyfikowaną zaróbką PL377740A1 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US42768002P 2002-11-19 2002-11-19

Publications (1)

Publication Number Publication Date
PL377740A1 true PL377740A1 (pl) 2006-02-20

Family

ID=32326579

Family Applications (1)

Application Number Title Priority Date Filing Date
PL377740A PL377740A1 (pl) 2002-11-19 2003-11-17 Kompozycje farmaceutyczne ze zmodyfikowaną zaróbką

Country Status (18)

Country Link
US (1) US7659061B2 (pl)
EP (1) EP1569693B1 (pl)
JP (1) JP4656945B2 (pl)
KR (1) KR20050085037A (pl)
CN (2) CN103272243A (pl)
AR (1) AR042193A1 (pl)
AU (1) AU2003276594B2 (pl)
BR (1) BR0316310A (pl)
CA (1) CA2502025C (pl)
IL (1) IL168183A (pl)
MX (1) MXPA05005319A (pl)
NO (1) NO20051688L (pl)
NZ (1) NZ539923A (pl)
PL (1) PL377740A1 (pl)
RU (1) RU2401127C2 (pl)
TW (1) TWI267379B (pl)
WO (1) WO2004045646A1 (pl)
ZA (1) ZA200503040B (pl)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010036427A1 (en) 2008-06-17 2010-04-01 Brigham Young University Cationic steroid antimicrobial diagnostic, detection, screening and imaging methods
KR20140063616A (ko) 2011-07-20 2014-05-27 브라이엄 영 유니버시티 소수성 세라게닌 화합물 및 이를 포함하는 기구
EP2755661B1 (en) 2011-09-13 2026-08-05 Brigham Young University Compositions for treating bone diseases and broken bones
BR112014005914B1 (pt) 2011-09-13 2021-11-09 Brigham Young University Produtos para cicatrização de feridas tecidulares
US9603859B2 (en) 2011-09-13 2017-03-28 Brigham Young University Methods and products for increasing the rate of healing of tissue wounds
US9694019B2 (en) 2011-09-13 2017-07-04 Brigham Young University Compositions and methods for treating bone diseases and broken bones
EP3449900A1 (en) 2011-12-21 2019-03-06 Brigham Young University Oral care compositions
US9533063B1 (en) 2012-03-01 2017-01-03 Brigham Young University Aerosols incorporating ceragenin compounds and methods of use thereof
CA2872399C (en) 2012-05-02 2021-01-12 Brigham Young University Ceragenin particulate materials and methods for making same
CA2888259C (en) 2012-10-17 2019-05-28 Brigham Young University Treatment and prevention of mastitis
AU2014203882B2 (en) 2013-01-07 2016-06-23 Brigham Young University Methods for reducing cellular proliferation and treating certain diseases
US10568893B2 (en) 2013-03-15 2020-02-25 Brigham Young University Methods for treating inflammation, autoimmune disorders and pain
BR112015023747B1 (pt) 2013-03-15 2023-04-18 Brigham Young University Uso de um composto antimicrobiano catiônico esteroide (csa) para a preparação de uma composição para tratar, reduzir, ou prevenir inflamação aguda ou crônica e/ou dor aguda ou crônica associada com uma doença ou um sintoma de doença
US11524015B2 (en) 2013-03-15 2022-12-13 Brigham Young University Methods for treating inflammation, autoimmune disorders and pain
US9387215B2 (en) 2013-04-22 2016-07-12 Brigham Young University Animal feed including cationic cholesterol additive and related methods
US11690855B2 (en) 2013-10-17 2023-07-04 Brigham Young University Methods for treating lung infections and inflammation
US20150203527A1 (en) 2014-01-23 2015-07-23 Brigham Young University Cationic steroidal antimicrobials
CA2844321C (en) 2014-02-27 2021-03-16 Brigham Young University Cationic steroidal antimicrobial compounds
US10220045B2 (en) 2014-03-13 2019-03-05 Brigham Young University Compositions and methods for forming stabilized compositions with reduced CSA agglomeration
US9867836B2 (en) 2014-03-13 2018-01-16 Brigham Young University Lavage and/or infusion using CSA compounds for increasing fertility in a mammal
US9931350B2 (en) 2014-03-14 2018-04-03 Brigham Young University Anti-infective and osteogenic compositions and methods of use
WO2015158823A1 (de) 2014-04-16 2015-10-22 Veyx-Pharma Gmbh Veterinärpharmazeutische zusammensetzung und deren verwendung
US9686966B2 (en) 2014-04-30 2017-06-27 Brigham Young University Methods and apparatus for cleaning or disinfecting a water delivery system
US10238665B2 (en) 2014-06-26 2019-03-26 Brigham Young University Methods for treating fungal infections
US10441595B2 (en) 2014-06-26 2019-10-15 Brigham Young University Methods for treating fungal infections
US10227376B2 (en) 2014-08-22 2019-03-12 Brigham Young University Radiolabeled cationic steroid antimicrobials and diagnostic methods
US10155788B2 (en) 2014-10-07 2018-12-18 Brigham Young University Cationic steroidal antimicrobial prodrug compositions and uses thereof
US9527883B2 (en) 2015-04-22 2016-12-27 Brigham Young University Methods for the synthesis of ceragenins
US10370403B2 (en) 2015-04-22 2019-08-06 Brigham Young University Methods for the synthesis of ceragenins
US9434759B1 (en) 2015-05-18 2016-09-06 Brigham Young University Cationic steroidal antimicrobial compounds and methods of manufacturing such compounds
US10226550B2 (en) 2016-03-11 2019-03-12 Brigham Young University Cationic steroidal antimicrobial compositions for the treatment of dermal tissue
US10959433B2 (en) 2017-03-21 2021-03-30 Brigham Young University Use of cationic steroidal antimicrobials for sporicidal activity
US12186328B2 (en) 2019-05-23 2025-01-07 Brigham Young University Use of CSA compounds to stimulate stem cells and hair growth

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US110561A (en) * 1870-12-27 Improvement in children s carriages
US4297353A (en) * 1980-08-04 1981-10-27 Sandoz, Inc. Non-irritating injectable dosage forms
KR890002631B1 (ko) * 1984-10-04 1989-07-21 몬산토 캄파니 생물학적으로 활성인 소마토트로핀을 지속적으로 유리하는 조성물
US5019395A (en) * 1988-03-08 1991-05-28 Warner-Lambert Company Compositions with enhanced penetration
JP2856444B2 (ja) * 1989-07-28 1999-02-10 呉羽化学工業株式会社 ビタミンｄ▲下３▼代謝産物製剤
JP3078859B2 (ja) * 1990-02-23 2000-08-21 武田薬品工業株式会社 安定な放出制御性製剤用コーティング剤
FR2692480B1 (fr) 1992-06-22 1995-12-08 Technico Flor Sa Nouvelles compositions cosmetiques ou alimentaires renfermant du copaiba.
ATE202109T1 (de) * 1993-03-12 2001-06-15 Upjohn Co Kristallines ceftiofur (freie säure)
DE4340879A1 (de) * 1993-12-01 1995-06-08 Horst P O Dr Wolf Arzneimittel zur Behandlung der Herzinsuffizienz
ATE252894T1 (de) 1995-01-05 2003-11-15 Univ Michigan Oberflächen-modifizierte nanopartikel und verfahren für ihre herstellung und verwendung
EP0914126B1 (en) 1996-06-27 2003-08-27 Janssen Pharmaceutica N.V. Sustained release sufentanil compositions
US5736151A (en) * 1996-12-09 1998-04-07 Pharmacia & Upjohn Company Antibiotic oil suspensions
US6074657A (en) 1997-03-20 2000-06-13 Pharmacia & Upjohn Company Administration of an injectable antibiotic in the ear of an animal
AU8832301A (en) 2000-09-12 2002-03-26 Upjohn Co Pharmaceutical composition having modified carrier
AU2001288322A1 (en) * 2000-09-12 2002-03-26 Pharmacia And Upjohn Company Llc Pharmaceutical composition having specific water activity

Also Published As

Publication number Publication date
US20040170650A1 (en) 2004-09-02
KR20050085037A (ko) 2005-08-29
TWI267379B (en) 2006-12-01
JP2006514629A (ja) 2006-05-11
US7659061B2 (en) 2010-02-09
IL168183A (en) 2010-04-29
RU2005115131A (ru) 2005-10-27
AU2003276594A1 (en) 2004-06-15
CN1713923A (zh) 2005-12-28
CN103272243A (zh) 2013-09-04
NO20051688D0 (no) 2005-04-05
BR0316310A (pt) 2005-09-27
WO2004045646A1 (en) 2004-06-03
NZ539923A (en) 2007-02-23
ZA200503040B (en) 2006-09-27
CA2502025A1 (en) 2004-06-03
EP1569693B1 (en) 2016-12-28
TW200427466A (en) 2004-12-16
RU2401127C2 (ru) 2010-10-10
MXPA05005319A (es) 2005-07-25
NO20051688L (no) 2005-08-02
EP1569693A1 (en) 2005-09-07
CA2502025C (en) 2013-07-02
JP4656945B2 (ja) 2011-03-23
AR042193A1 (es) 2005-06-15
AU2003276594B2 (en) 2009-01-08

Similar Documents

Publication Publication Date Title
GB2389530B (en) Pharmaceutical compositions
AU2003291103A8 (en) Pharmaceutical composition
GB0218625D0 (en) Pharmaceutical compounds
IL164547A0 (en) Pharmaceutical composition
AU2003276549A8 (en) Pharmaceutical compositions containing a biguanide-glitazone combination
GB2391473B (en) Pharmaceutical compositions
IL165878A0 (en) Pharmaceutical composition
GB0215775D0 (en) Pharmaceutical compounds
HU0302441D0 (en) Pharmaceutical compositions having antibiothic effect
GB0229258D0 (en) Medicinal compositions
GB0213481D0 (en) Pharmaceutical compositions
GB0206505D0 (en) Pharmaceutical combination
AU2003291642A8 (en) Pyrazoloazepine compounds as pharmaceutical agents
AU2003208621A1 (en) A pharmaceutical composition
GB0201520D0 (en) Pharmaceutical uses
PL373409A1 (pl) Kombinacja farmaceutyczna
GB0204392D0 (en) Pharmaceutical compound
PL370907A1 (pl) Kompozycje farmaceutyczne
GB0217703D0 (en) Pharmaceutical composition
GB0221068D0 (en) Pharmaceutical compositions
GB0225880D0 (en) Pharmaceutical compositions
GB0209379D0 (en) Pharmaceutical compositions
GB0210663D0 (en) Pharmaceutical compositions
GB0210905D0 (en) Pharmaceutical composition
GB0214491D0 (en) Pharmaceutical composition